KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin (2016 - 2026)

TherapeuticsMD filings provide 16 years of EBITDA Margin readings, the most recent being 99.86% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 22609.0% to 99.86% in Q1 2026 year-over-year; TTM through Mar 2026 was 114.29%, a 20380.0% increase, with the full-year FY2025 number at 145.27%, up 20181.0% from a year prior.
  • EBITDA Margin hit 99.86% in Q1 2026 for TherapeuticsMD, up from 173.8% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 32264.66% in Q2 2022 to a low of 8182.2% in Q3 2022.
  • Median EBITDA Margin over the past 5 years was 207.31% (2024), compared with a mean of 384.12%.
  • Biggest five-year swings in EBITDA Margin: soared 3245009bps in 2022 and later plummeted -3281706bps in 2023.
  • TherapeuticsMD's EBITDA Margin stood at 113.32% in 2022, then crashed by -255bps to 175.9% in 2023, then surged by 44bps to 97.75% in 2024, then crashed by -78bps to 173.8% in 2025, then skyrocketed by 43bps to 99.86% in 2026.
  • The last three reported values for EBITDA Margin were 99.86% (Q1 2026), 173.8% (Q4 2025), and 109.95% (Q3 2025) per Business Quant data.